Explore the urgent legal, ethical, and clinical challenges in emergency psychiatry, share cases and tips, and contribute to Psychiatric Times’ November series.
|Videos|October 7, 2020
Debating Our Social Psychiatric Problems
Author(s)H. Steven Moffic, MD
Dr Moffic talks about the impact of current political events on the public's mental health.
Advertisement
Psychiatry & Society
Dr Moffic is an award-winning psychiatrist who has specialized in the cultural and ethical aspects of psychiatry. A prolific writer and speaker, he received the one-time designation of being a Hero of Public Psychiatry from the Assembly of the American Psychiatric Association in 2002. He has recently been leading Tikkun Olam advocacy movements on climate instability, burnout, Islamophobia, and anti-Semitism for a better world. He serves on the Editorial Board of Psychiatric Times®.
Advertisement
Related to this article
Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
BCG vaccination curbs tau tangles in mice by boosting microglial cleanup, fueling hopes for human trials to reduce dementia risk.
GLP-1 weight-loss drugs may worsen eating disorders or mask symptoms; experts urge careful screening, specialist referral, and monitoring before, during, and after use.
Sabirnetug phase 2 Alzheimer trial misses cognitive endpoint despite lowering amyloid, prompting Acumen to halt development and open-label extension plans.
Check out our pipeline updates from October!
Psychedelic trials often exclude real-world comorbidities; clinicians must weigh blinding limits, dosing durability, support needs, safety risks, and uneven system readiness.
HHS updates its national dementia plan, prioritizing risk reduction, early detection, biomarkers, and faster diagnostics and treatments through new FDA, CMS, and ARPA-H initiatives.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Assessing Interventions for Insomnia in Peri- and Postmenopausal Women
2
October 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
3
ALKS 7290 for Adjunctive Treatment for MDD Enters Phase 2 Study
4
GLP-1 Receptor Agonists May Reinforce Restriction in Patients With Eating Disorders
5